Cencora, Inc. (COR)
NYSE: COR · Real-Time Price · USD
292.87
-1.51 (-0.51%)
At close: Jul 18, 2025, 4:00 PM
287.77
-5.10 (-1.74%)
After-hours: Jul 18, 2025, 7:32 PM EDT
Cencora Revenue
Cencora had revenue of $75.45B in the quarter ending March 31, 2025, with 10.29% growth. This brings the company's revenue in the last twelve months to $310.23B, up 12.18% year-over-year. In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B with 12.12% growth.
Revenue (ttm)
$310.23B
Revenue Growth
+12.18%
P/S Ratio
0.18
Revenue / Employee
$6,744,178
Employees
46,000
Market Cap
56.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
| Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
| Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
| Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
| Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
COR News
- 16 days ago - Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release - Business Wire
- 7 weeks ago - Cencora Elects Lori J. Ryerkerk to Its Board of Directors - Business Wire
- 2 months ago - Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs - Seeking Alpha
- 2 months ago - Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings - Benzinga
- 2 months ago - Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Cencora raises annual profit forecast on strong demand for specialty drugs - Reuters
- 2 months ago - Cencora Reports Fiscal 2025 Second Quarter Results - Business Wire
- 3 months ago - 3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock - Barrons